Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
Asahi Kasei reports developments across a diversified global business that includes healthcare, materials, electronic components, and hydrogen-related technologies. News commonly covers pharmaceutical pipeline expansion, specialty pharmaceutical acquisitions, antiviral and autoimmune-disease programs, and subsidiary activity involving Veloxis Pharmaceuticals, Asahi Kasei Therapeutics, and Asahi Kasei Pharma.
Company updates also include Asahi Kasei Microdevices' magnetic-sensor and photonic technology work, chlor-alkali electrolysis products such as electrolyzer cells, ion-exchange membranes, and electrodes, and Aqualyzer™ alkaline-water electrolyzer deployments for hydrogen production. Recurring themes include research collaborations, license agreements, clinical and regulatory disclosures, material agreements, capital-structure updates, and operating and financial results.
Asahi Kasei has announced a strategic partnership with Genomatica to develop biomass-derived hexamethylenediamine (HMD), enhancing the production of sustainable polyamide 66 (Leona™). This collaboration allows Asahi Kasei to evaluate bio-HMD as a feedstock, aiming to be first-to-market in sustainable engineering plastics for automotive and electronics. Asahi Kasei targets carbon neutrality by 2050, with bio-HMD potentially reducing greenhouse gas emissions. The partnership aligns with increasing global demand for eco-friendly materials in manufacturing.
Asahi Kasei Medical plans to expand its production capacity for Planova™ filters by constructing a new assembly plant in Nobeoka, Miyazaki, Japan. This facility aims to enhance manufacturing automation and efficiency, with construction set to begin in Q3 2022 and completion expected in early 2024. The demand for Planova™ filters has surged due to the COVID-19 pandemic's impact on the biotherapeutics market. Asahi Kasei Medical has been investing in production capacity to meet this demand, reinforcing its position as a market leader in virus filtration.
ZOLL Medical Corporation has successfully completed its acquisition of Itamar Medical Ltd. for $1.0333 per ordinary share, totaling approximately $31 per American Depository Share. Itamar Medical will operate as a division within ZOLL, focusing on sleep-disordered breathing diagnostics. The integration is expected to leverage ZOLL's global infrastructure to drive growth while maintaining operations in Caesarea, Israel. Following the acquisition, Itamar Medical's shares will cease trading on the Nasdaq and TASE markets, and it will deregister its securities with the SEC.
Summary not available.
ZOLL Medical Corporation has announced a definitive agreement to acquire Itamar Medical Ltd. for approximately $538 million. This acquisition will enable ZOLL to enhance its services for undiagnosed cardiac patients suffering from sleep apnea. Itamar’s WatchPAT device, which is FDA-cleared, is a key component in this integration to improve diagnosis and treatment in the cardiopulmonary sector. The deal represents a premium of 50.2% over Itamar's stock price on September 10, 2021, and is expected to close by the end of 2021.